ProCE Banner Activity

COVID-19 Vaccination in Patients With CLL: Where Do We Stand?

Clinical Thought
Early prospective data show a low rate of seroconversion in patients with CLL who received COVID-19 mRNA vaccines. How can we improve vaccine protection against COVID-19 in this vulnerable patient population?

Released: August 27, 2021

Expiration: August 26, 2022

Share

Faculty

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pharmacyclics AbbVie Company Janssen Biotech admin Janssen Sci

Faculty Disclosure

Primary Author

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, and Janssen.